USANA Health Sciences Inc. - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 28, 1998. USANA Health Sciences Inc. develops, manufactures, and distributes nutritional, personal, and skin care products through a network of independent distributors. Primary markets include the United States and Canada, with operations commencing in Australia and New Zealand in February 1998. The company operates as a single business segment, with nutritionals accounting for approximately 81% of sales.
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 |
|---|---|---|
| Net Sales | $26.2 million | $17.7 million |
| Gross Profit | $20.7 million (79.0% margin) | $13.9 million (78.5% margin) |
| Net Earnings | $1.9 million | $1.1 million |
| Diluted EPS | $0.28 | $0.17 |
| Cash from Operations | $3.7 million | $2.2 million |
| Cash and Equivalents (End of Period) | $4.0 million | $1.3 million |
| Working Capital | $5.6 million | N/A |
| Debt (Line of Credit) | $0 outstanding | N/A |
Liquidity: The company maintains a $5.0 million line of credit with no outstanding balance as of March 28, 1998. Management believes current cash and credit availability are sufficient for the next twelve months.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 48.0% year-over-year, driven by a 37.3% increase in the distributor base (92,000 vs. 67,000) and the launch of Australian and New Zealand markets.
- Profitability: Net earnings rose 72.7% to $1.9 million. Profit margin improved to 7.3% from 6.2% due to a price increase implemented in late 1997 and production efficiencies.
- Expense Trends:
- Distributor Incentives: Increased 42.2% to $11.8 million but decreased as a percentage of sales to 45.0% (from 46.9%) due to pricing strategy changes.
- SG&A: Increased 58.8% to $5.4 million (20.6% of sales) due to variable costs, increased depreciation on IT equipment, and amortization of new market launch costs.
- Balance Sheet: Inventory increased by $2.1 million to $8.6 million, primarily due to extended transit times for international shipments and preparation for the annual convention.
Outlook, Risks, and Contingencies
- Guidance: Management does not provide specific numerical guidance but expects current cash and credit lines to cover needs for the next 12 months. Additional financing may be required if operating environments turn adverse.
- Legal Proceedings: USANA is defending a patent infringement lawsuit filed by International Nutrition Company (INC) regarding the Proflavanol product. A French court ruled INC does not own the patent in question; the decision is on appeal. If upheld, INC may be barred from proceeding.
- Year 2000 Risk: The company is ensuring internal systems are Y2K compliant but notes potential risks from third-party providers.
- Operational Risks: Key risks include new product development uncertainty, competition, pricing pressures, and foreign currency fluctuations.
Investor Verification Checklist
- Verify the status of the French appellate court ruling regarding the INC patent infringement lawsuit.
- Monitor the sustainability of distributor growth rates following the initial surge in Australia and New Zealand.
- Review the impact of the 1997 price increase on long-term sales volume versus margin expansion.
- Assess the company's ability to manage inventory levels as international logistics stabilize.
- Confirm compliance with financial covenants on the $5.0 million line of credit.